NCT02608216: [18F]FLT PET/CT in Rb+ Metastatic Breast Cancer

NCT02608216
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: Rb+
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Other, Serine-Threonine Kinase Inhibitor, Chemotherapy

Key Eligibility Criteria:

Gender: Female
Age: 18 Years and older ¬† (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patient must have one metastatic site outside of the liver & bone; Patient must be eligible for the phase I study of ribociclib (LEE011) and weekly paclitaxel (https://clinicaltrials.gov/ct2/show/NCT02599363)
Exclusions: 
https://ClinicalTrials.gov/show/NCT02608216

Comments are closed.

Up ↑